APA (7th ed.) Citation

Oza, A. M., Estevez-Diz, M., Grischke, E., Hall, M., Marmé, F., Provencher, D., . . . Moore, K. (2020). A biomarker-enriched, randomized phase II trial of Adavosertib (AZD1775) plus Paclitaxel and Carboplatin for women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clinical cancer research, 26(18), . https://doi.org/10.1158/1078-0432.CCR-20-0219

Chicago Style (17th ed.) Citation

Oza, Amit M., et al. "A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer." Clinical Cancer Research 26, no. 18 (2020). https://doi.org/10.1158/1078-0432.CCR-20-0219.

MLA (9th ed.) Citation

Oza, Amit M., et al. "A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer." Clinical Cancer Research, vol. 26, no. 18, 2020, https://doi.org/10.1158/1078-0432.CCR-20-0219.